Tag #Pharmaceuticals

Showing 73 to 84 of 151 results

dutchnews.nl

🌐 85% Global Worthiness

Apr 9, 19:19

EU-US Trade War: AEX Index Drops 3%, Retaliatory Tariffs Announced

The escalating US-EU trade war, triggered by US tariffs on steel, resulted in a 3% drop in the AEX index on Wednesday, impacting companies like Besi, Philips, Shell, and ASM International; the EU responded with €22 billion in retaliatory tariffs on US goods, while global sea container bookings to th...

EU-US Trade War: AEX Index Drops 3%, Retaliatory Tariffs Announced

The escalating US-EU trade war, triggered by US tariffs on steel, resulted in a 3% drop in the AEX index on Wednesday, impacting companies like Besi, Philips, Shell, and ASM International; the EU responded with €22 billion in retaliatory tariffs on US goods, while global sea container bookings to th...

Progress

44% Bias Score

ShareSaveArticle

Decent Work and Economic Growth

12345678

Previous 1 of 8 Next

What are the immediate economic impacts of the escalating US-EU trade war on European markets and specific companies?

The escalating US-EU trade war, marked by a 25% US tariff on steel and retaliatory EU tariffs on various US products (including tobacco, meat, cosmetics, and soy), caused a 3% drop in the AEX blue chip index by mid-afternoon on Wednesday. Besi, Philips, Shell, and ASM International suffered significant losses. The EU aims for negotiated solutions but proceeds with tariffs taking effect this week, with further rounds planned for May and December.

pt.euronews.com

🌐 85% Global Worthiness

Apr 3, 22:15

US spares pharmaceuticals from tariffs, but EU remains wary

The US temporarily exempted pharmaceutical products from new tariffs, avoiding a major economic disruption to both the US and EU, although future tariffs remain a concern, particularly for Ireland, Belgium and Germany.

US spares pharmaceuticals from tariffs, but EU remains wary

The US temporarily exempted pharmaceutical products from new tariffs, avoiding a major economic disruption to both the US and EU, although future tariffs remain a concern, particularly for Ireland, Belgium and Germany.

Progress

44% Bias Score

ShareSaveArticle

Decent Work and Economic Growth

12345678

Previous 1 of 8 Next

What are the long-term implications of this tariff situation, considering the history of US tax policy and the EU's pharmaceutical sector dependence?

The US's 2017 tax reforms inadvertently spurred EU pharmaceutical production growth, particularly in Ireland, due to US companies seeking tax advantages. Future tariffs could reverse this trend, impacting jobs and economic output in the EU. The EU's continued concern underscores the need for proactive strategies to manage this transatlantic trade relationship and mitigate future economic risks.

zeit.de

🌐 75% Global Worthiness

Apr 2, 16:09

Boehringer Ingelheim's 2024 Revenue Up 6.1%, Faces US Tariff, Regulatory Challenges

Boehringer Ingelheim reported a 6.1% increase in 2024 revenue (€26.8 billion), driven by strong sales of Jardiance and Nexgard, while investing €6.2 billion in R&D and facing potential US tariff impacts and regulatory hurdles in Germany.

Boehringer Ingelheim's 2024 Revenue Up 6.1%, Faces US Tariff, Regulatory Challenges

Boehringer Ingelheim reported a 6.1% increase in 2024 revenue (€26.8 billion), driven by strong sales of Jardiance and Nexgard, while investing €6.2 billion in R&D and facing potential US tariff impacts and regulatory hurdles in Germany.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How is Boehringer Ingelheim addressing the challenges posed by potential US tariffs and regulatory delays in Germany?

Boehringer Ingelheim's success stems from its key products' growth and substantial R&D investment. Regionalizing supply chains, as exemplified by Jardiance's US production, mitigates risks. However, future US tariffs and potential delays in German drug approvals (Zongertinib) pose challenges.

zeit.de

🌐 75% Global Worthiness

Mar 27, 13:17

German Court Rules on Data Privacy for Online Non-Prescription Drug Sales

The German Federal Court of Justice ruled that online sales of non-prescription medications on platforms like Amazon require explicit customer consent for data collection, aligning with GDPR regulations regarding sensitive health data and impacting the approximately 20% market share of online sales ...

German Court Rules on Data Privacy for Online Non-Prescription Drug Sales

The German Federal Court of Justice ruled that online sales of non-prescription medications on platforms like Amazon require explicit customer consent for data collection, aligning with GDPR regulations regarding sensitive health data and impacting the approximately 20% market share of online sales ...

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the BGH's decision regarding data privacy in online medication sales connect to existing EU regulations and prior case law?

This decision connects to broader concerns about data privacy in e-commerce, particularly regarding sensitive health information. The BGH's judgment aligns with a prior European Court of Justice ruling, highlighting the importance of informed consent for processing personal data. Failure to obtain such consent constitutes a GDPR violation, impacting online pharmacies and marketplaces.

es.euronews.com

🌐 85% Global Worthiness

Mar 15, 16:12

EU's Critical Medicines Act: 'Buy European' Clause and Funding Concerns

The European Commission's proposed Critical Medicines Act aims to improve EU medicine supply security through a 'Buy European' clause, new medicine categories, and improved joint procurement, but faces criticism for insufficient funding (€83 million for 2026-2027) and the lack of contingency stockpi...

EU's Critical Medicines Act: 'Buy European' Clause and Funding Concerns

The European Commission's proposed Critical Medicines Act aims to improve EU medicine supply security through a 'Buy European' clause, new medicine categories, and improved joint procurement, but faces criticism for insufficient funding (€83 million for 2026-2027) and the lack of contingency stockpi...

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the long-term risks of the absence of a harmonized EU-wide framework for contingency stockpiling of critical medicines?

The Act's success hinges on overcoming funding limitations and potential trade conflicts. The lack of a coordinated contingency stockpiling framework weakens the overall resilience of the EU's medicine supply chain. Future implications include strained international relations and uneven access to essential medicines across member states.

gr.euronews.com

🌐 85% Global Worthiness

Mar 15, 22:12

EU's Critical Medicines Act: Securing Drug Supply Amid Budgetary and Stockpiling Concerns

The European Commission unveiled its Critical Medicines Act, aiming to secure the EU's drug supply by prioritizing EU-based suppliers via a "Buy European" clause, promoting domestic production, and enhancing joint procurement mechanisms, but facing criticism over its limited budget and lack of emerg...

EU's Critical Medicines Act: Securing Drug Supply Amid Budgetary and Stockpiling Concerns

The European Commission unveiled its Critical Medicines Act, aiming to secure the EU's drug supply by prioritizing EU-based suppliers via a "Buy European" clause, promoting domestic production, and enhancing joint procurement mechanisms, but facing criticism over its limited budget and lack of emerg...

Progress

32% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the Critical Medicines Act address the issue of insufficient EU production of critical medicines?

The "Buy European" initiative aims to reduce reliance on third-country suppliers, potentially sparking trade disputes. The proposal also promotes increased domestic production of critical medicines, but without mandating European manufacturing, focusing instead on strategic partnerships with neighboring countries.

cincodias.elpais.com

🌐 85% Global Worthiness

Apr 6, 10:09

US Vaccine Makers Face Stock Plunge Amidst Anti-Vaccine Sentiment

Amidst global trade shifts and political uncertainty, European pharmaceutical companies largely avoided losses while US vaccine makers faced significant stock drops following the appointment of Robert F. Kennedy Jr. as US Assistant Secretary of Health and the resignation of a key FDA official, Peter...

US Vaccine Makers Face Stock Plunge Amidst Anti-Vaccine Sentiment

Amidst global trade shifts and political uncertainty, European pharmaceutical companies largely avoided losses while US vaccine makers faced significant stock drops following the appointment of Robert F. Kennedy Jr. as US Assistant Secretary of Health and the resignation of a key FDA official, Peter...

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How do the differing performances of European and US pharmaceutical companies reflect broader geopolitical and regulatory factors?

The contrasting performance highlights the impact of US political climate on the sector. While European firms benefited from exemption from new tariffs, US vaccine manufacturers suffered double-digit losses due to the appointment of Robert F. Kennedy Jr., a known anti-vaccine advocate, and the subsequent resignation of a key FDA official, Peter Marks, who criticized Kennedy's misinformation.

welt.de

🌐 75% Global Worthiness

Apr 2, 16:09

Boehringer Ingelheim's 2024 Sales Surge Driven by Jardiance, but US Pricing and EU Regulations Pose Challenges

Boehringer Ingelheim reported €21.9 billion in human pharmaceutical sales in 2024, a 7% increase year-over-year, driven by Jardiance (€8.4 billion), while animal health sales reached €4.7 billion, with Nexgard (€1.35 billion) leading the growth; the company invested €6.2 billion in R&D and anticipat...

Boehringer Ingelheim's 2024 Sales Surge Driven by Jardiance, but US Pricing and EU Regulations Pose Challenges

Boehringer Ingelheim reported €21.9 billion in human pharmaceutical sales in 2024, a 7% increase year-over-year, driven by Jardiance (€8.4 billion), while animal health sales reached €4.7 billion, with Nexgard (€1.35 billion) leading the growth; the company invested €6.2 billion in R&D and anticipat...

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What were the key financial results for Boehringer Ingelheim in 2024, and what factors drove this performance?

Boehringer Ingelheim reported a 7% increase in human pharmaceutical sales to €21.9 billion in 2024, driven by a 14%+ surge in Jardiance sales to €8.4 billion. Animal health sales also grew by 1.9% to €4.7 billion, with Nexgard sales increasing by 14% to €1.35 billion. The company invested €6.2 billion in R&D, anticipating several new product launches, potentially two in 2025.

africa.chinadaily.com.cn

🌐 90% Global Worthiness

Mar 28, 10:11

AI Revolutionizes Protein Design: Shanghai Breakthrough Cuts Modification Time

Shanghai scientists created the world's largest protein sequence database, Venus-Pod (9 billion sequences), and AI models (Venus series) to drastically reduce protein modification time from years to months, impacting various industries.

AI Revolutionizes Protein Design: Shanghai Breakthrough Cuts Modification Time

Shanghai scientists created the world's largest protein sequence database, Venus-Pod (9 billion sequences), and AI models (Venus series) to drastically reduce protein modification time from years to months, impacting various industries.

Progress

36% Bias Score

ShareSaveArticle

Industry, Innovation, and Infrastructure

12345678

Previous 1 of 8 Next

What are the key components of the Venus system, and how do they contribute to accelerated protein engineering?

The AI-powered approach replaces trial-and-error protein modification, enabling precise enhancements like heat resistance and alkaline stability. This is achieved through AI-directed protein evolution and AI-powered screening using the Venus models, which are top-ranked in predicting and designing protein functions.

smh.com.au

🌐 85% Global Worthiness

Mar 23, 01:11

Australia's Slow Drug Subsidy Process Sparks US Trade Dispute

Australia's Pharmaceutical Benefits Scheme (PBS) faces delays averaging 466 days for new drug subsidies, compared to 90 days in other countries, impacting patient access and drawing US trade concerns, prompting a government review with 50 recommendations for improvement.

Australia's Slow Drug Subsidy Process Sparks US Trade Dispute

Australia's Pharmaceutical Benefits Scheme (PBS) faces delays averaging 466 days for new drug subsidies, compared to 90 days in other countries, impacting patient access and drawing US trade concerns, prompting a government review with 50 recommendations for improvement.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate consequences of Australia's slow approval process for new medicines under the PBS?

Australia's Pharmaceutical Benefits Scheme (PBS) faces delays in subsidizing new medicines, averaging 466 days compared to 90 days in other countries. This impacts patient access to affordable treatments, with some forced to pay thousands for private options while waiting. The slow process has drawn US pharmaceutical complaints, raising trade dispute concerns.

fr.euronews.com

🌐 85% Global Worthiness

Mar 15, 16:12

EU's Critical Medicines Act: "Buy European" Policy and Funding Concerns

The European Commission's proposed Critical Medicines Act aims to improve essential medicine supply within the EU, using a "Buy European" principle and increased domestic production but facing limited funding (€83 million for 2026-2027) and a lack of emergency stockpile coordination.

EU's Critical Medicines Act: "Buy European" Policy and Funding Concerns

The European Commission's proposed Critical Medicines Act aims to improve essential medicine supply within the EU, using a "Buy European" principle and increased domestic production but facing limited funding (€83 million for 2026-2027) and a lack of emergency stockpile coordination.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How will the proposed Critical Medicines Act address the current shortage of essential medicines within the EU, and what are the potential drawbacks of its approach?

The "Buy European" approach, while aiming to improve supply security, risks protectionism, mirroring China's policies that the EU criticized. Increased European production is encouraged, but not mandated within the EU; collaboration with neighboring countries is planned. The lack of a coordinated EU-wide emergency stockpile is a significant omission.

elpais.com

🌐 85% Global Worthiness

Mar 12, 01:11

EU Proposes Critical Medicines Act to Diversify Pharmaceutical Supply Chain

The European Commission's proposed Critical Medicines Act aims to diversify the EU's pharmaceutical supply chain, reducing its dependence on China and India, and incentivize domestic production of essential medicines like antibiotics to enhance healthcare security.

EU Proposes Critical Medicines Act to Diversify Pharmaceutical Supply Chain

The European Commission's proposed Critical Medicines Act aims to diversify the EU's pharmaceutical supply chain, reducing its dependence on China and India, and incentivize domestic production of essential medicines like antibiotics to enhance healthcare security.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What immediate actions are proposed by the European Commission to mitigate the EU's dependence on external sources for essential medicines?

The European Commission proposed the "Critical Medicines Act" to reduce the EU's dependence on China and India for essential medicines. This act aims to diversify the supply chain and incentivize domestic production of crucial medicines, addressing vulnerabilities exposed during the COVID-19 pandemic.

Showing 73 to 84 of 151 results